Nimotuzumab treatment of malignant gliomas

Expert Opinion on Biological Therapy

Volumn 12, Issue 12, 2012, Pages 1649-1659

  Bode, Udo ^a   Massimino, Maura ^b   Bach, Ferdinand ^c   Zimmermann, Martina ^a   Khuhlaeva, Elena ^d   Westphal, Manfred ^e   Fleischhack, Gudrun ^a,f  

^a UNIVERSITY OF BONN   (Germany)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c ONCOSCIENCE AG   (Germany)

^d BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

^e UNIVERSITY OF HAMBURG   (Germany)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

EGFR antagonists; EGFR antibodies; Glioma; Malignant glioma; Nimotuzumab; Paediatric brain tumours; Pontine glioma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NAVELBINE; NIMOTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMOZOLOMIDE;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHILDHOOD CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; DERMATITIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; ERYTHEMA; GLIOBLASTOMA; HUMAN; HYPOMAGNESEMIA; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CHILD; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; SIGNAL TRANSDUCTION;

EID: 84869449735     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.733367     Document Type: Review

References (54)

1. Massimino M, Bode U, Biassoni V, et al. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 2011;11:247-56
2. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: Ready for personalized medicine? Nat Rev Neurol 2010;6:39-51
3. Zawlik I, Vaccarella S, Kita D, et al. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: A population-based study. Neuroepidemiology 2009;32:21-9
4. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J Clin Oncol 2009;34:5743-50
5. Criniere E, Kaloshi G, Laigle-Donadey F, et al. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 2007;83:173-9
6. Dunn J, Baborie A, Alam F, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 2009;101:124-31
7. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27(35):5874-80
8. van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009;27(35):5881-6
9. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66
10. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8
11. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009;16:748-54
12. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24
13. Macdonald TJ, Aguilera D, Kramm CM. Treatment of high-grade glioma in children and adolescents. Neuro Oncol 2011;13:1049-58
14. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: Critical review in clinical trials. Lancet Oncol 2006;7:241-8
15. Paugh BS, Ou C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveal key differences with the adult disease. J Clin Oncol 2010;18:3061-8
16. Warren KE, Killian K, Suuriniemi M, et al. Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. Neuro Oncol 2012;12:326-32
17. Paugh BS, Broniscer A, Ou C, et al. Genome-wide analyses identify amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 2011;29:3999-4006
18. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse pontine gliomas highlights platelet-derived growth factor receptor a and Poly (ADPribose) as potential therapeutic targets. J Clin Oncol 2010;28:1337-44
19. Gilbertson RJ, Hill DA, Hernan R, et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 2003;9:3620-4
20. Li G, Mitra SS, Monje M, et al. Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. J Neurooncol 2012; Epub ahead of print 21. Verhaak RGW, Hoadly KA, Purdom E, et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 2010;17:98-110
21. Puget S, Philippe C, Bax DA, et al. Mesenchymal transition and PGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic gliomas PLoS one. 2012;7(2):1-14
22. Broniscer A. Past, present and future strategies in the treatment of high-grade glioma in children. Cancer Invest 2006;24:77-81
23. Wolff JE, Driever PH, Erdlenbruch B, et al. Intensive chemotherapy improves survival in pediaetric high-grade glioma after gross total resection: Results of the HIT-GBM-C protocol. Cancer 2010;116:705-12
24. Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: A report from the Children's Oncology Group. Neuro Oncol 2011;13:410-16
25. Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: A report from the Children's Oncology Group. Neuro Oncol 2011;13:317-23
26. Chassot A, Canale S, Varlet P, et al. Radiotherapy with concurrent and adjuvant temzolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol 2012;106:399-407
27. MacDonald TJ, Arenson EB, Ater J, et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: Final analysis of Children's Cancer Group Study 9933. Cancer 2005;104:2862-71
28. Dunkel IJ, Garvin JH, Goldmann S, et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group. J Neurooncol 1998;37:67-73
29. Geyer R, Stewart CF, Kokak M, et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem glioma and supratentorial malignant gliomas. Eur J Cancer 2010;46:3287-93
30. Goerger B, Hargrave D, Thomas E, et al. Innovative therapies for children with cancer: Phase I study of erlotinib in pediatric brainstem glioma and relapsing/refractory brain tumors. Neuro-Oncol 2011;13:109-18
31. Haas-Kogan DA, Banerjee A, Poussaint TY, et al. Phase II study of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro-Oncol 2011;13:298-306
32. Frappaz D, Schell M, Thiesse P, et al. Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas. Final results of BSG 98 prospective trial. Neuro-Oncol 2008;10:599-607
33. Wagner S, Warmuth-Metz M, Emser A, et al. Treatment options in childhood pontine gliomas. J Neurooncol 2006;79:281-7
34. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of panitumumab, matuzumab, nimotzuzmab and zalutumumab. Acta Oncol 2008;47:9-19
35. Lo KM, Lan Y, Zhang X. The role of ADCC effector function in the anti-tumour efficacy of anti-EGFR antibodies in a mouse xenograft model [abstract A123]. AACR-NCI-EORTC Conf Mol Targets Cancer Ther; 2003
36. Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657-70
37. Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs 2009;1:41-8
38. Crombet T, Osorio M, Cruz T, et al. Use of the humanized antiEpidermal Growth Factor Receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54
39. You B, Brade A, Magalhaes JM, et al. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs 2011;29:996-1003
40. Garrido G, Tikhomirow IA, Rabasa A, et al. Bivalent binding by intermediate affinity of nimotuzumab. A contribution to explain antibody clinical profile. Cancer Biol Ther 2011;11:373-82
41. Talavera A, Friemann R, Gomez-Puerta S, et al. Nimotuzumab, an antitumour antibody that targets the epidermal growth factor receptor, blocks ligant binding while permitting the active receptor conformation. Cancer Res 2009;69:5851-9
42. Strumberg D, Schultheis B, Scheulen ME, et al. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Int J Clin Pharmacol Ther 2010;48:473-5
43. Fichtner I, Nowak CH. Report: Biodistribution of nimotuzumab in xenografted mice. Experimental Pharmacology & Oncology; 22 April 2010; Berlin 45. Crombet T, Torres O, Rodriguez V, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor in advanced brain tumor patients: Preliminary study. Hybridoma 2001;20:131-6
44. Diaz Miqueli A, Rolff J, Lemm M, et al. Radiosensitation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer 2009;100:950-8
45. Rojo F, Gracias E, Villena N, et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: A SENDO Foundation Study. Clin Cancer Res 2010;16:2474-82
46. Crombet T, Torres L, Neninger E, et al. Pharmacological evaluation of humanized Anti-Epidermal Growth Factor Receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003;26:139-48
47. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines in solid tomours. Europ. Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Institute of Cancer Kanada. J Natl Cancer Inst 2000;92:205-16
48. Bode U, Buchen M, Warmuth-Metz M, et al. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade glioams in children and adolescents. J Clin Oncol 2006;24(Suppl 18):1522
49. Hilger R, Bach F, Strumberg D, Fleischhack G. Pharmacokinetic study of the humanized anti-EGF-receptor monoclonal antibody nimotuzumab in infant and adult patients [abstract #211].99th AACR Annual Meeting; 12 - 16 April 2008; San Diego, CA 52. Bode U, Windelberg M, Massimino M, et al. Phase III trial of nimotuzumab for the treatment of newly diagnosted diffuse intrinsic pontine gliomas in children and adolescents. J Clin Oncol 2008;26(Suppl 15):2058
50. Massimino M, Biassoni V, Gandola L, et al. Nimotuzumab and vinorelbine concomitantly to radiation as maintenance for diffuse pontine glioma in childhood: Promising results on a series of 20 patients [abstract 32]. ISPNO Congress; 6/2012; Toronto 54. Ramos TC, Figueredo J, Catala M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. Cancer Biol Ther 2006;5:375-9
51. Solomon MT, Selva JC, Figueredo J, et al. Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients. J Clin Oncol 2012;30(Suppl): Abstract 2515
52. Westphal M, Bach F. Final results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard radiation and temozolomide. J Clin Oncol 2012;30(Suppl): Abstract 2033
53. Wolff JE, Rytting ME, Vats TS, et al. Treatment of recurrent diffuse intrinsic pontine glioma: The MD Anderson Cancer Center experience. J Neurooncol 2012;106:391-7
54. Stupp R, Mason W, van den Bent M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96